Structural basis of the major TMPRSS2 promoter G-quadruplex and its complex with berberine

Abstract

TMPRSS2 plays a crucial role in facilitating the entry of both the influenza virus and the SARS-CoV-2 coronavirus into host cells. Recent studies have identified a guanine-rich sequence in the proximal promoter region of the TMPRSS2 gene, which can form G-quadruplex structures (TMPRSS2-G4s) that are potential targets for small molecules to inhibit TMPRSS2 expression. However, the structural details of the major TMPRSS2-G4 and its complex with small molecules remain unknown, hindering the development of antiviral drugs targeting TMPRSS2-G-quadruplexes (G4s). This study reports the first high-resolution nuclear magnetic resonance (NMR) solution structure of the major TMPRSS2-G4, which consists of a three-tetrad core parallel-stranded G4. Both 3′ and 5′ flanking regions form well-defined capping structures stabilized by multiple hydrogen bonds. Importantly, we found that berberine, an antiviral alkaloid, strongly binds to the major TMPRSS2-G4 and determined its binding complex structure with TMPRSS2-G4 at a 2∶1 binding stoichiometry. Each berberine molecule recruits an adjacent flanking residue, forming a coplanar structure superimposed on two outer G-tetrads. Moreover, we demonstrated that the major TMPRSS2-G4 can stably form within a longer deoxyribonucleic acid (DNA) context and be targeted by small molecules to inhibit DNA polymerase activity. Overall, this study provides structural insights into the recognition mechanism of small molecules by the major TMPRSS2-G4 and may facilitate the development of novel antiviral therapeutics targeting TMPRSS2-G4.

Keywords

DNA G-quadruplex / NMR solution structure / TMPRSS2 / Berberine / Antivirus

Funding

This research was supported by the National Natural Science Foundation of China (Nos. 82322065, 82173707, and 82204241), the Innovation and Entrepreneurship (Shuangchuang) Program of Jiang-su Province (2024), the Natural Science Foundation of Jiangsu Province (No. BK20221039), the Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University, No. SKLNMZZ2024JS12), the Fundamental Research Funds for the Central Universities (No. 2632025ZD06), and the Scientific Research Foundation for High-level Faculty, China Pharmaceutical University (No. 3150020065).

Supporting information

The supporting information is available free of charge at: DNA sequences, tables of proton chemical shifts and NOEs, EMSA, 2D-NOESY, ¹H−¹³C HSQC, DQF-COSY, side view of structures, 5′- and 3′-end capping structures, fluorescence measurement, chemical shift differences, and CD spectra.

Notes

This research was supported by the National Natural Science Foundation of China (Nos. 82322065, 82173707, and 82204241), the Innovation and Entrepreneurship (Shuangchuang) Program of Jiang-su Province (2024), the Natural Science Foundation of Jiangsu Province (No. BK20221039), the Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University, No. SKLNMZZ2024JS12), the Fundamental Research Funds for the Central Universities (No. 2632025ZD06), and the Scientific Research Foundation for High-level Faculty, China Pharmaceutical University (No. 3150020065).

Declaration of competing interest

These authors have no conflict of interest to declare.

References

[1] Kim S. TMPRSS4, a type II transmembrane serine protease, as a potential therapeutic target in cancer. Exp Mol Med. 2023; 55(4):716-724. https://doi.org/10.1038/s12276-023-00975-5.

[2] Vorstandlechner V, Laggner M, Copic D, et al. The serine proteases dipeptidyl-peptidase 4 and urokinase are key molecules in human and mouse scar formation. Nat Commun. 2021; 12(1):6242. https://doi.org/10.1038/s41467-021-26495-2.

[3] Tanabe LM, List K. The role of type II transmembrane serine protease-mediated signaling in cancer. FEBS J. 2017; 284(10):1421-1436. https://doi.org/10.1111/febs.13971.

[4] Barré O, Dufour A, Eckhard U, et al. Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide libraries. PLoS One. 2014; 9(9):e105984. https://doi.org/10.1371/journal.pone.0105984.

[5] Shapira T, Monreal IA, Dion SP, et al. ATMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022; 605(7909):340-348. https://doi.org/10.1038/s41586-022-04661-w.

[6] Bastus NC, Boyd LK, Mao X, et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 2010; 70(23):9544-9548. https://doi.org/10.1158/0008-5472.CAN-10-1638.

[7] Lu Q, Nunez E, Lin C, et al. A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants. Nucleic Acids Res. 2008; 36(20):e130. https://doi.org/10.1093/nar/gkn585.

[8] Saunders N, Fernandez I, Planchais C, et al. TMPRSS2 is a functional receptor for human coronavirus HKU1. Nature. 2023; 624(7990):207-214. https://doi.org/10.1038/s41586-023-06761-7.

[9] Steiner S, Kratzel A, Barut GT, et al. SARS-CoV-2 biology and host interactions. Nat Rev Microbiol. 2024; 22(4):206-225. https://doi.org/10.1038/s41579-023-01003-z.

[10] Gautam A, Boyd DF, Nikhar S, et al. Necroptosis blockade prevents lung injury in severe influenza. Nature. 2024; 628(8009):835-843. https://doi.org/10.1038/s41586-024-07265-8.

[11] Chu H, Hou Y, Yang D, et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature. 2022; 609(7928):785-792. https://doi.org/10.1038/s41586-022-05148-4.

[12] Wei X, Zhou Y, Shen X, et al. Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein. Acta Pharm Sin B. 2024; 14(6):2505-2519. https://doi.org/10.1016/j.apsb.2024.03.009.

[13] Liu W, Zhao Y, Fan J, et al. Smoke and spike: benzo[a]pyrene enhances SARS-CoV-2 infection by boosting NR4A2-induced ACE2 and TMPRSS2 expression. Adv Sci (Weinh). 2023; 10(26):e2300834. https://doi.org/10.1002/advs.202300834.

[14] Gowthaman R, Guest JD, Yin R, et al. CoV3D:a database of high resolution coronavirus protein structures. Nucleic Acids Res. 2021; 49(D1):D282-D287. https://doi.org/10.1093/nar/gkaa731.

[15] Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021; 6(1):134. https://doi.org/10.1038/s41392-021-00558-8.

[16] Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020; 78(4):779-784.e5. https://doi.org/10.1016/j.molcel.2020.04.022.

[17] Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm Sin B. 2021; 11(1):1-12. https://doi.org/10.1016/j.apsb.2020.10.006.

[18] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052.

[19] Hifumi T, Isokawa S, Otani N, et al. Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients. Crit Care. 2020; 24(1):497. https://doi.org/10.1186/s13054-020-03227-4.

[20] Shen LW, Qian MQ, Yu K, et al. Inhibition of influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 gene G-quadruplex and hence down-regulating TMPRSS2 expression. Sci Rep. 2020; 10(1):7635. https://doi.org/10.1038/s41598-020-64368-8.

[21] Zhao C, Qin G, Niu J, et al. Targeting RNA G-quadruplex in SARS-CoV-2: a promising therapeutic target for COVID-19? Angew Chem Int Ed Engl. 2021; 60(1):432. https://doi.org/10.1002/anie.202011419.

[22] Hänsel-Hertsch R, Di Antonio M, Balasubramanian S. DNA G-quadruplexes in the human genome: detection, functions and therapeutic potential. Nat Rev Mol Cell Biol. 2017; 18(5):279-284. https://doi.org/10.1038/nrm.2017.3.

[23] Wang KB, Wang Y, Dickerhoff J, et al. DNA G-quadruplexes as targets for natural product drug discovery. Engineering. 2024; 38:39-51. https://doi.org/10.1016/j.eng.2024.03.015.

[24] Wang KB, Dickerhoff J, Wu G, et al. PDGFR-β promoter forms a vacancy G-quadruplex that can be filled in by dGMP: solution structure and molecular recognition of guanine metabolites and drugs. J Am Chem Soc. 2020; 142(11):5204-5211. https://doi.org/10.1021/jacs.9b12770.

[25] Wang KB, Liu Y, Li Y, et al. Oxidative damage induces a vacancy G-quadruplex that binds guanine metabolites: solution structure of a cGMP fill-in vacancy G-quadruplex in the oxidized BLM gene promoter. J Am Chem Soc. 2022; 144(14):6361-6372. https://doi.org/10.1021/jacs.2c00435.

[26] Robinson J, Raguseo F, Nuccio SP, et al. DNA G-quadruplex structures: more than simple roadblocks to transcription? Nucleic Acids Res. 2021; 49(15):8419-8431. https://doi.org/10.1093/nar/gkab609.

[27] Zheng KW, Zhang JY, He YD, et al. Detection of genomic G-quadruplexes in living cells using a small artificial protein. Nucleic Acids Res. 2020; 48(20):11706-11720. https://doi.org/10.1093/nar/gkaa841.

[28] de Nicola B, Lech CJ, Heddi B, et al. Structure and possible function of a G-quadruplex in the long terminal repeat of the proviral HIV-1 genome. Nucleic Acids Res. 2016; 44(13):6442-6451. https://doi.org/10.1093/nar/gkw432.

[29] Murat P, Zhong J, Lekieffre L, et al. G-quadruplexes regulate epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nat Chem Biol. 2014; 10(5):358-364. https://doi.org/10.1038/nchembio.1479.

[30] Métifiot M, Amrane S, Litvak S, et al. G-quadruplexes in viruses: function and potential therapeutic applications. Nucleic Acids Res. 2014; 42(20):12352-12366. https://doi.org/10.1093/nar/gku999.

[31] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/ 1981 to 09/2019. J Nat Prod. 2020; 83(3):770-803. https://doi.org/10.1021/acs.jnatprod.9b01285.

[32] Luo Z, Yin F, Wang X, et al. Progress in approved drugs from natural product resources. Chin J Nat Med. 2024; 22(3):195-211. https://doi.org/10.1016/S1875-5364(24)60582-0.

[33] Li T, Huang M, Lu J. Cancer statistics and trends in China: the potential of natural product application. Chin J Nat Med. 2024; 22(8):673-675. https://doi.org/10.1016/S1875-5364(24)60649-7.

[34] Hu Q, Zhang Y, Chen P, et al. Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 M^pro from the antiviral herb Ephedra. Chin J Nat Med. 2024; 22(9):797-807. https://doi.org/10.1016/S1875-5364(24)60577-7.

[35] Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004; 203(2):127-137. https://doi.org/10.1016/j.canlet.2003.09.002.

[36] Tian Y, Tang G, Gao Y, et al. Carrier-free small molecular self-assembly based on berberine and curcumin incorporated in submicron particles for improving antimicrobial activity. ACS Appl Mater Interfaces. 2022; 14(8):10055-10067. https://doi.org/10.1021/acsami.1c22900.

[37] Zhang S, Xu P, Zhu Z, et al. Acetylation of p65^Lys310 by p300 in macrophages mediates anti-inflammatory property of berberine. Redox Biol. 2023; 62:102704. https://doi.org/10.1016/j.redox.2023.102704.

[38] Khan S, Hussain A, Attar F, et al. A review of the berberine natural polysaccharide nanostructures as potential anticancer and antibacterial agents. Biomed Pharmacother. 2022; 146:112531. https://doi.org/10.1016/j.biopha.2021.112531.

[39] Valipour M, Zakeri KZ, Abdollahi E, et al. Recent applications of protoberberines as privileged starting materials for the development of novel broad-spectrum antiviral agents: a concise review (2017-2023). ACS Pharmacol Transl Sci. 2024; 7(1):48-71. https://doi.org/10.1021/acsptsci.3c00292.

[40] Babalghith AO, Al-Kuraishy HM, Al-Gareeb AI, et al. The role of berberine in Covid-19: potential adjunct therapy. Inflammopharmacology. 2022; 30(6):2003-2016. https://doi.org/10.1007/s10787-022-01080-1.

[41] Liu G, Du W, Sang X, et al. RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection. Nat Commun. 2022; 13(1):1444. https://doi.org/10.1038/s41467-022-29135-5.

[42] Wang KB, Liu Y, Li J, et al. Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine. Nat Commun. 2022; 13(1):6016. https://doi.org/10.1038/s41467-022-33761-4.

[43] Dickerhoff J, Jang J, Yang D. Best method to determine DNA G-quadruplex folding: the ¹H-¹³C HSQC NMR experiment. Methods. 2024; 221:35-41. https://doi.org/10.1016/j.ymeth.2023.11.013.

[44] Wang KB, Dickerhoff J, Yang D. Solution structure of ternary complex of berberine bound to a dGMP-fill-in vacancy G-quadruplex formed in the PDGFR-β promoter. J Am Chem Soc. 2021; 143(40):16549-16555. https://doi.org/10.1021/jacs.1c06200.

[45] Humphrey W, Dalke A, Schulten K.VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-38. https://doi.org/10.1016/0263-7855(96)00018-5.

[46] Li XM, Zheng KW, Zhang JY, et al. Guanine-vacancy-bearing G-quadruplexes responsive to guanine derivatives. Proc Natl Acad Sci U S A. 2015; 112(47):14581-14586. https://doi.org/10.1073/pnas.1516925112.

[47] Wang KB, Elsayed MSA, Wu G, et al. Indenoisoquinoline topoisomerase inhibitors strongly bind and stabilize the MYC promoter G-quadruplex and downregulate MYC. J Am Chem Soc. 2019; 141(28):11059-11070. https://doi.org/10.1021/jacs.9b02679.

[48] Liu Y, Li J, Zhang Y, et al. Structure of the major G-quadruplex in the human EGFR oncogene promoter adopts a unique folding topology with a distinctive Snap-Back loop. J Am Chem Soc. 2023; 145(29):16228-16237. https://doi.org/10.1021/jacs.3c05214.

[49] Dickerhoff J, Brundridge N, McLuckey SA, et al. Berberine molecular recognition of the parallel MYC G-quadruplex in solution. J Med Chem. 2021; 64(21):16205-16212. https://doi.org/10.1021/acs.jmedchem.1c01508.

[50] Wang ZF, Li MH, Chu IT, et al. Cytosine epigenetic modification modulates the formation of an unprecedented G 4 structure in the WNT1 promoter. Nucleic Acids Res. 2020; 48(3):1120-1130. https://doi.org/10.1093/nar/gkz1207.

[51] Yang D, Okamoto K. Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem. 2010; 2(4):619-646. https://doi.org/10.4155/fmc.09.172.

[52] Del Villar-Guerra R, Trent JO, Chaires JB. G-quadruplex secondary structure obtained from circular dichroism spectroscopy. Angew Chem Int Ed Engl. 2018; 57(24):7171-7175. https://doi.org/10.1002/anie.201709184.

[53] Kerkour A, Marquevielle J, Ivashchenko S, et al. High-resolution three-dimensional NMR structure of the KRAS proto-oncogene promoter reveals key features of a G-quadruplex involved in transcriptional regulation. J Biol Chem. 2017; 292(19):8082-8091. https://doi.org/10.1074/jbc.M117.781906.

[54] Lin C, Dickerhoff J, Yang D. NMR studies of G-quadruplex structures and G-quadruplex-interactive compounds. Methods Mol Biol. 2019; 2035:157-176. https://doi.org/10.1007/978-1-4939-9666-7_9.

[55] Dickerhoff J, Dai J, Yang D. Structural recognition of the MYC promoter G-quadruplex by a quinoline derivative: insights into molecular targeting of parallel G-quadruplexes. Nucleic Acids Res. 2021; 49(10):5905-5915. https://doi.org/10.1093/nar/gkab330.

[56] Zheng Z, Li X, Nie K, et al. Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets. Front Immunol. 2023; 14:1038651. https://doi.org/10.3389/fimmu.2023.1038651.

[57] Kotar A, Wang B, Shivalingam A, et al. NMR structure of a triangulenium-based long-lived fluorescence probe bound to a G-quadruplex. Angew Chem Int Ed Engl. 2016; 55(40):12508-12511. https://doi.org/10.1002/anie.201606877.

[58] He YD, Zheng KW, Wen CJ, et al. Selective targeting of guanine-vacancy-bearing G-quadruplexes by G-quartet complementation and stabilization with a guanine-peptide conjugate. J Am Chem Soc. 2020; 142(26):11394-11403. https://doi.org/10.1021/jacs.0c00774.

[59] Takahashi S, Kotar A, Tateishi-Karimata H, et al. Chemical modulation of DNA replication along G-quadruplex based on topology-dependent ligand binding. J Am Chem Soc. 2021; 143(40):16458-16469. https://doi.org/10.1021/jacs.1c05468.

[60] Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov. 2011; 10(4):261-275. https://doi.org/10.1038/nrd3428.

[61] Siddiqui-Jain A, Grand CL, Bearss DJ, et al. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A. 2002; 99(18):11593-11598. https://doi.org/10.1073/pnas.182256799.

[62] Verma A, Yadav VK, Basundra R, et al. Evidence of genome-wide G4 DNA-mediated gene expression in human cancer cells. Nucleic Acids Res. 2009; 37(13):4194-4204. https://doi.org/10.1093/nar/gkn1076.

[63] Figueroa GB, Souza SD, Pereira HS, et al. Development of a single-domain antibody to target a G-quadruplex located on the hepatitis B virus covalently closed circular DNA genome. J Med Virol. 2024; 96(6):e29692. https://doi.org/10.1002/jmv.29692.

[64] Ruggiero E, Richter SN. G-quadruplexes and G-quadruplex ligands: targets and tools in antiviral therapy. Nucleic Acids Res. 2018; 46(7):3270-3283. https://doi.org/10.1093/nar/gky187.

[65] Liu D, Chen C, Chen D, et al. Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2. Proc Natl Acad Sci U S A. 2023; 120(4):e2202820120. https://doi.org/10.1073/pnas.2202820120.

[66] Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS-CoV-2 virus. Cell. 2020; 183(3):730-738.e13. https://doi.org/10.1016/j.cell.2020.09.018.

[67] de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14(8):523-534. https://doi.org/10.1038/nrmicro.2016.81.

[68] Xiong Q, Cao L, Ma C, et al. Close relatives of MERS-CoV in bats use ACE 2 as their functional receptors. Nature. 2022; 612(7941):748-757. https://doi.org/10.1038/s41586-022-05513-3.

[69] Farag M, Mouawad L. Comprehensive analysis of intramolecular G-quadruplex structures: furthering the understanding of their formalism. Nucleic Acids Res. 2024; 52(7):3522-3546. https://doi.org/10.1093/nar/gkae182.